CA2923166A1 - Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy - Google Patents

Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy Download PDF

Info

Publication number
CA2923166A1
CA2923166A1 CA2923166A CA2923166A CA2923166A1 CA 2923166 A1 CA2923166 A1 CA 2923166A1 CA 2923166 A CA2923166 A CA 2923166A CA 2923166 A CA2923166 A CA 2923166A CA 2923166 A1 CA2923166 A1 CA 2923166A1
Authority
CA
Canada
Prior art keywords
subject
breast cancer
biological sample
subtype
luminal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2923166A
Other languages
English (en)
French (fr)
Inventor
Maggie Chon U. CHEANG
Torsten O. NEILSEN
Charles M. Perou
Matthew J. Ellis
Philip S. Bernard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
British Columbia Cancer Agency BCCA
University of North Carolina at Chapel Hill
Washington University in St Louis WUSTL
University of Utah Research Foundation Inc
Original Assignee
British Columbia Cancer Agency BCCA
University of North Carolina at Chapel Hill
Washington University in St Louis WUSTL
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Columbia Cancer Agency BCCA, University of North Carolina at Chapel Hill, Washington University in St Louis WUSTL, University of Utah Research Foundation Inc filed Critical British Columbia Cancer Agency BCCA
Publication of CA2923166A1 publication Critical patent/CA2923166A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G01N33/57515—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2923166A 2013-09-09 2014-09-09 Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy Abandoned CA2923166A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361875373P 2013-09-09 2013-09-09
US61/875,373 2013-09-09
US201461990948P 2014-05-09 2014-05-09
US61/990,948 2014-05-09
PCT/US2014/054760 WO2015035377A1 (en) 2013-09-09 2014-09-09 Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy

Publications (1)

Publication Number Publication Date
CA2923166A1 true CA2923166A1 (en) 2015-03-12

Family

ID=51688397

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2923166A Abandoned CA2923166A1 (en) 2013-09-09 2014-09-09 Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy

Country Status (7)

Country Link
US (1) US20150072021A1 (enExample)
EP (1) EP3044332A1 (enExample)
JP (1) JP2016537010A (enExample)
AU (1) AU2014317843A1 (enExample)
CA (1) CA2923166A1 (enExample)
IL (1) IL244421A0 (enExample)
WO (1) WO2015035377A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
ES2650610T3 (es) 2008-05-30 2018-01-19 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
KR102602507B1 (ko) 2014-11-24 2023-11-14 나노스트링 테크놀로지스, 인크. 유전자 정제 및 이미징을 위한 방법 및 장치
AU2015359479A1 (en) * 2014-12-09 2017-06-15 King's College London Breast cancer treatment with taxane therapy
MX2018005867A (es) 2015-11-13 2018-09-21 Biotheranostics Inc Integracion de las caracteristicas tumorales con el indice de cancer de mama.
CN114191428B (zh) 2016-03-02 2024-09-24 卫材研究发展管理有限公司 基于艾日布林的抗体-药物偶联物和使用方法
CN107574243B (zh) * 2016-06-30 2021-06-29 博奥生物集团有限公司 分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
CN108456730B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种复发风险基因群作为标志物在制备评估乳腺癌分子分型内远处复发风险的产品中的应用
EP3946383A4 (en) * 2019-04-04 2023-05-03 University of Utah Research Foundation MULTIGENE TEST TO EVALUATE THE RISK OF CANCER RECURRENCE
KR102414754B1 (ko) * 2019-10-10 2022-06-30 주식회사 종근당 직장암 항암화학방사선 치료 반응 예측용 바이오마커
TW202129008A (zh) * 2019-11-05 2021-08-01 香港商行動基因（智財）有限公司 檢測異檸檬酸脫氫酶突變的套組及方法
EP3945136A1 (en) * 2020-07-28 2022-02-02 Hospital Clínic de Barcelona In vitro method for the prognosis of patients suffering from her2-positive breast cancer
CN113278700B (zh) * 2021-06-04 2022-08-09 浙江省肿瘤医院 一种用于乳腺癌分型及预后预测的引物组及试剂盒
KR20240081508A (ko) 2022-11-17 2024-06-10 인제대학교 산학협력단 Dna 메틸화 변화를 통한 방사선치료 반응성 예측용 바이오마커 조성물 및 이의 용도
CN116622885B (zh) * 2023-05-23 2025-01-10 福建省农业科学院果树研究所 一种用于不同桃花色鉴定的分子标记方法及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
AU669489B2 (en) 1991-09-18 1996-06-13 Affymax Technologies N.V. Method of synthesizing diverse collections of oligomers
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
EP0916396B1 (en) 1991-11-22 2005-04-13 Affymetrix, Inc. (a Delaware Corporation) Combinatorial strategies for polymer synthesis
US5856174A (en) 1995-06-29 1999-01-05 Affymetrix, Inc. Integrated nucleic acid diagnostic device
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
WO1999023254A1 (en) 1997-10-31 1999-05-14 Affymetrix, Inc. Expression profiles in adult and fetal organs
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
CA2574447A1 (en) 2004-07-15 2006-01-26 University Of Utah Research Foundation Housekeeping genes and methods for identifying the same
EP1954708A4 (en) 2005-11-23 2009-05-13 Univ Utah Res Found Methods and compositions involving intrinsic genes
ATE525482T1 (de) 2005-12-23 2011-10-15 Nanostring Technologies Inc Nanoreporter und verfahren zu deren herstellung und verwendung
WO2007076132A2 (en) 2005-12-23 2007-07-05 Nanostring Technologies, Inc. Compositions comprising oriented, immobilized macromolecules and methods for their preparation
US7892740B2 (en) * 2006-01-19 2011-02-22 The University Of Chicago Prognosis and therapy predictive markers and methods of use
EP2155899A2 (en) 2007-04-10 2010-02-24 Nanostring Technologies, Inc. Methods and computer systems for identifying target-specific sequences for use in nanoreporters
CA2698569A1 (en) * 2007-09-06 2009-09-03 Mark G. Erlander Tumor grading and cancer prognosis
CA2699376C (en) * 2007-09-14 2018-10-23 University Of South Florida Gene signature for the prediction of radiation therapy response
ES2650610T3 (es) 2008-05-30 2018-01-19 The University Of North Carolina At Chapel Hill Perfiles de expresión génica para predecir desenlaces en cáncer de mama
US8519115B2 (en) 2008-08-14 2013-08-27 Nanostring Technologies, Inc. Stable nanoreporters
WO2013082440A2 (en) * 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
MX369628B (es) 2012-05-22 2019-11-14 Nanostring Technologies Inc Genes nano46 y metodos para predecir el resultado del cancer de mama.

Also Published As

Publication number Publication date
JP2016537010A (ja) 2016-12-01
US20150072021A1 (en) 2015-03-12
EP3044332A1 (en) 2016-07-20
IL244421A0 (en) 2016-04-21
AU2014317843A1 (en) 2016-03-24
WO2015035377A1 (en) 2015-03-12

Similar Documents

Publication Publication Date Title
US20230272476A1 (en) Nano46 genes and methods to predict breast cancer outcome
CA2923166A1 (en) Methods and kits for predicting outcome and methods and kits for treating breast cancer with radiation therapy
US20140037620A1 (en) Methods of Treating Breast Cancer with Gemcitabine Therapy
US9181588B2 (en) Methods of treating breast cancer with taxane therapy
US9066963B2 (en) Methods of treating breast cancer with anthracycline therapy
US20160115551A1 (en) Methods to predict risk of recurrence in node-positive early breast cancer
US20160160293A1 (en) Breast cancer treatment with taxane therapy

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190910

FZDE Discontinued

Effective date: 20190910